On October 2, 2026, AC Immune SA held an Extraordinary General Meeting where shareholders elected Tom Graney as a Member of the Board of Directors. This decision is significant for the company as it seeks to strengthen its leadership and strategic direction in the pharmaceutical preparations sector.

Background

AC Immune SA, incorporated in Switzerland, operates in the pharmaceutical preparations industry (SIC 2834). The company is listed on the Nasdaq under the ticker ACIU. It focuses on developing innovative therapies for neurodegenerative diseases, aiming to address significant unmet medical needs.

What the Filing Says

The filing states, "AC Immune shareholders approved the election of Tom Graney as Member of the Board of Directors until the end of the Annual General Meeting 2027." Further details regarding the meeting will be available on AC Immune's website within 15 days.

Impact

This election may positively affect AC Immune's governance and strategic initiatives. Graney's expertise could enhance the company's decision-making processes and its ability to compete effectively in the pharmaceutical sector.

What's Next

Further details regarding the meeting and the election will be published in the minutes on AC Immune’s website. The filing does not specify what happens next.

Company Information

AC Immune SA is incorporated in Switzerland and operates under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. The company's principal executive offices are located at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland. It is also noteworthy that AC Immune is listed on the Nasdaq exchange under the ticker symbol ACIU.

Shareholder Approval

The election of Tom Graney as a Member of the Board of Directors received the necessary approval from AC Immune shareholders during the Extraordinary General Meeting. This approval is crucial as it reflects the shareholders' confidence in Graney's ability to contribute to the company's governance and strategic direction.

Future Filings

The filing indicates that this report on Form 6-K will be incorporated by reference into several registration statements on Form F-3 and Form S-8. This means that the information contained within this report will be considered part of the company's official filings with the SEC, which may have implications for future capital raising efforts and compliance.

Additional Context

The filing does not include specific details regarding the qualifications or background of Tom Graney, nor does it elaborate on the strategic initiatives that AC Immune plans to pursue under his leadership. Furthermore, there is no discussion of any other agenda items that may have been considered during the Extraordinary General Meeting.